Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/261229
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients |
Autor: | Janusz, Kamila; Martín-Izquierdo, Marta; López Cadenas, Félix; Ramos, Fernando; Hernandez-Sánchez, Jesus M.; Lumbreras, Eva CSIC ORCID; Robledo, Cristina; Sánchez-del-Real, Javier; Caballero, Juan-Carlos; Collado, Rosa; Bernal, T.; Pedro, Carmen; Insunza, Andrés; Paz, Raquel de; Xicoy, Blanca; Salido, Eduardo; Sanchez-Garcia, Joaquin; Santos-Mínguez, Sandra; Miguel, Cristina; Simón Muñoz, Ana María; Sánchez Barba, Mercedes; Hernández, Jesús M. CSIC ORCID ; Abáigar, María CSIC; Díez-Campelo, María | Palabras clave: | MDS SF3B1 Splicing NGS |
Fecha de publicación: | 2021 | Editor: | Springer Nature | Citación: | Annals of Hematology 100: 1995- 2004 (2021) | Resumen: | SF3B1 is a highly mutated gene in myelodysplastic syndrome (MDS) patients, related to a specific subtype and parameters of good prognosis in MDS without excess blasts. More than 40% of MDS patients carry at least two myeloid-related gene mutations but little is known about the impact of concurrent mutations on the outcome of MDS patients. In applying next-generation sequencing (NGS) with a 117 myeloid gene custom panel, we analyzed the co-occurrence of SF3B1 with other mutations to reveal their clinical, biological, and prognostic implications in very low/low- and intermediate-risk MDS patients. Mutations in addition to those of SF3B1 were present in 80.4% of patients (median of 2 additional mutations/patient, range 0–5). The most frequently mutated genes were as follows: TET2 (39.2%), DNMT3A (25.5%), SRSF2 (10.8%), CDH23 (5.9%), and ASXL1, CUX1, and KMT2D (4.9% each). The presence of at least two mutations concomitant with that of SF3B1 had an adverse impact on survival compared with those with the SF3B1 mutation and fewer than two additional mutations (median of 54 vs. 87 months, respectively: p = 0.007). The co-occurrence of SF3B1 mutations with specific genes is also linked to a dismal prognosis: SRSF2 mutations were associated with shorter overall survival (OS) than SRSF2wt (median, 27 vs. 75 months, respectively; p = 0.001), concomitant IDH2 mutations (median OS, 11 [mut] vs. 75 [wt] months; p = 0.001), BCOR mutations (median OS, 11 [mut] vs. 71 [wt] months; p = 0.036), and NUP98 and STAG2 mutations (median OS, 27 and 11 vs. 71 months, respectively; p = 0.008 and p = 0.002). Mutations in CHIP genes (TET2, DNMT3A) did not significantly affect the clinical features or outcome. Our results suggest that a more comprehensive NGS study in low-risk MDS SF3B1mut patients is essential for a better prognostic evaluation. | Versión del editor: | http://dx.doi.org/10.1007/s00277-020-04360-4 | URI: | http://hdl.handle.net/10261/261229 | DOI: | 10.1007/s00277-020-04360-4 | ISSN: | 0939-5555 | E-ISSN: | 1432-0584 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
8
checked on 26-mar-2024
WEB OF SCIENCETM
Citations
7
checked on 22-feb-2024
Page view(s)
63
checked on 19-abr-2024
Download(s)
11
checked on 19-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.